Session 12: Equity Investments: Valuation Models Reading 46: Private Company Valuation
LOS i: Demonstrate the market approaches to private company valuation (for example, guideline public company method, guideline transaction method, and prior transaction method), and discuss the advantages and disadvantages of each.
A private pharmaceutical firm is under consideration for acquisition where the financial buyer will pay with equity. Part of the payment to the sellers is based on FDA approval of the firm’s drug. If the analyst uses a market approach and comparable data from public firms, which of the following would most likely result in a price-multiple that is too high? The comparable data is:
A) |
from transactions where the buyer used cash. | |
|
C) |
for transactions where the consideration was non-contingent. | |
In market approaches, the analyst values the subject private firm using price multiples from previous public and private transactions. A strategic buyer is one who will have synergies with the target whereas a financial buyer does not. A financial transaction typically has a smaller price premium. So in this case, the comparable price-multiple will be too high.
If the acquisition involves the acquirer’s stock, the acquirer may be using overvalued shares to buy their target. Using comparables where cash is the consideration would result in lower price multiples.
Contingent consideration is payment to the sellers based on the achievement of specific goals such as FDA approval. Contingent consideration increases the risk to the seller and ceteris paribus, they would demand a higher price. Using comparables where the consideration was non-contingent would result in lower price multiples.
|